Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierWe are a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib or AF), left atrial appendage (LAA) management and post-operative pain management. Afib is an irregular heartbeat, or arrhythmia, which affects over 59 million people worldwide and is a growing epidemic. It is the most common cardiac arrhythmia encountered in clinical practice and results in high utilization of healthcare services and significant cost burden.
In the company’s own words · 10-K filed Feb 19, 2026 · SEC EDGAR
Business segments
Jun 2026 · $80.1MThe company’s own SEC segment disclosure.
- United States$40.9M51%
- Europe$17.2M21%
- Non Us$11.2M14%
- Asia Pacific$8.6M11%
- Other International$2.2M3%
AtriCure, Inc. (ATRC) reported revenue of $141M in Q1 2026 (quarter ended Mar 31, 2026), up 14% from the same quarter a year earlier. That came with a gross margin of 77% and net income of $108K (0.1% of revenue). For the full year FY2025, revenue was $535M (+15% year on year) and net income −$11M. Its largest region in Jun 2026 was United States at $41M, 51% of the disclosed total, well ahead of Europe at 21%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Medical Instruments & Supplies
Ranks #1 of 19 by Smart Score